Literature DB >> 18336517

Haemodialysis for children under the age of two years.

Clemente Neves Sousa1, Madalena Gama, Melanie Andrade, M Sameiro Faria, Eloi Pereira.   

Abstract

Less than 10% of children under 2 years old with end-stage renal failure in Europe and in the United States of America are treated with haemodialysis. For small children, peritoneal dialysis is often the preferred treatment. Haemodialysis is chosen for a very small number of children, and is only used in some selected centres because of its highly complex technique, the difficulties related to vascular access, and the need to have a skilled and experienced nursing and medical team. With the technological development of recent years, the quality of dialysis treatment offered to paediatric patients has improved considerably and haemodialysis is presently considered to be a safe and efficient treatment for acute or chronic paediatric renal impairment. However, because a successful renal transplant continues to be linked to a better quality of life for children with terminal chronic renal impairment, dialysis ought to be regarded as a temporary treatment method, while waiting for a renal transplant.

Entities:  

Mesh:

Year:  2008        PMID: 18336517     DOI: 10.1111/j.1755-6686.2008.00004.x

Source DB:  PubMed          Journal:  J Ren Care        ISSN: 1755-6678


  2 in total

1.  Chronic haemodialysis in small children: a retrospective study of the Italian Pediatric Dialysis Registry.

Authors:  Fabio Paglialonga; Silvia Consolo; Carmine Pecoraro; Enrico Vidal; Bruno Gianoglio; Flora Puteo; Stefano Picca; Maria Teresa Saravo; Alberto Edefonti; Enrico Verrina
Journal:  Pediatr Nephrol       Date:  2015-12-21       Impact factor: 3.714

2.  Serial measurement of electrolyte and citrate concentrations in blood-primed continuous hemodialysis circuits during closed-circuit dialysis.

Authors:  Daisuke Saito; Takuya Fujimaru; Yoshihiro Inoue; Tomoyuki Hirayama; Itaru Ezaki; Hassu Kin; Takuya Shuo; Masaaki Nakayama; Yasuhiro Komatsu
Journal:  Pediatr Nephrol       Date:  2019-08-01       Impact factor: 3.714

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.